Key result
This review summarizes the epidemiology, pathophysiology, clinical features, and current management strategies for heart failure with preserved ejection fraction, with a specific focus on women.
Why the study?
HFpEF pathophysiology remains incompletely understood with limited therapies proven to improve long-term outcomes, and women are particularly likely to present with this phenotype.
This review highlights the epidemiology, pathophysiology, and management of HFpEF, emphasizing its distinct clinical features and higher prevalence in elderly women.
Highlights HFpEF burden and features in women; leaves open sex-specific trials before practice change.
In the current era of cardiovascular disease, the diagnosis of heart failure with preserved ejection fraction (HFpEF) is a well-recognized clinical entity that is equally prevalent but distinctly different from heart failure with reduced ejection fraction (HFrEF). Despite normal EF patients with this disease have similar morbidity and mortality rates compared with HFrEF, as well as a rising rate of hospitalizations. The pathophysiology of HFpEF is incompletely understood. The number of therapies with proven efficacy at improving longterm cardiovascular outcomes is limited. Women with heart failure syndromes, particularly the elderly, are much more likely to have a HFpEF phenotype at the time of their diagnosis. The purpose of this paper is to review the epidemiology, pathophysiology, clinical features, and current management strategies in HFpEF, especially as it pertains to women.
No takes yet. Share an insight, caveat, or question.
Vilaro et al. (2019) conducted a review in Heart failure with preserved ejection fraction (HFpEF). This review summarizes the epidemiology, pathophysiology, clinical features, and current management strategies for heart failure with preserved ejection fraction, with a specific focus on women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: